|
20 Sep 2025 |
Lupin
|
Consensus Share Price Target
|
2055.60 |
2228.05 |
- |
8.39 |
buy
|
|
|
|
|
15 Apr 2024
|
Lupin
|
Sharekhan
|
2055.60
|
1868.00
|
1611.45
(27.56%)
|
Target met |
Buy
|
|
|
|
|
13 Feb 2024
|
Lupin
|
SBI Securities
|
2055.60
|
1838.00
|
1608.75
(27.78%)
|
Target met |
Buy
|
|
|
|
|
09 Feb 2024
|
Lupin
|
Axis Direct
|
2055.60
|
1770.00
|
1622.10
(26.72%)
|
Target met |
Buy
|
|
|
Double-digit growth in India business as the company has already increased MR numbers to 1,000, 4) An uptick in the API business as the API industry is witnessing demand revival. Recommendation: BUY
|
|
09 Feb 2024
|
Lupin
|
BOB Capital Markets Ltd.
|
2055.60
|
1560.00
|
1622.10
(26.72%)
|
Target met |
Hold
|
|
|
Strong Q3 with EBITDA/PAT of Rs 10.2bn/Rs 6.1bn, beating consensus by 17%/42%
|
|
09 Feb 2024
|
Lupin
|
Prabhudas Lilladhar
|
2055.60
|
1600.00
|
1622.10
(26.72%)
|
Target met |
Hold
|
|
|
|
|
08 Feb 2024
|
Lupin
|
Motilal Oswal
|
2055.60
|
1480.00
|
1606.40
(27.96%)
|
|
Neutral
|
|
|
|
|
15 Nov 2023
|
Lupin
|
Geojit BNP Paribas
|
2055.60
|
1276.00
|
1170.25
(75.65%)
|
Target met |
Hold
|
|
|
|
|
11 Nov 2023
|
Lupin
|
BOB Capital Markets Ltd.
|
2055.60
|
1050.00
|
1180.15
(74.18%)
|
|
Sell
|
|
|
Q2 EBITDA/PAT overtook consensus by 16%/25% backed by strong US business from gSpiriva launch and robust margins
|
|
10 Nov 2023
|
Lupin
|
Axis Direct
|
2055.60
|
1325.00
|
1180.15
(74.18%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
10 Nov 2023
|
Lupin
|
Sharekhan
|
2055.60
|
1274.00
|
1170.25
(75.65%)
|
Target met |
Hold
|
|
|
|